Curriculum Vitaes
Profile Information
- Affiliation
- Department of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine
- Degree
- 博士(医学)(名古屋大学)
- ORCID ID
https://orcid.org/0009-0005-2667-7057
- J-GLOBAL ID
- 202001000562143382
- researchmap Member ID
- R000010558
Research Areas
6Research History
6-
Sep, 2024 - Present
-
Apr, 2023 - Present
-
Apr, 2023 - Present
-
Jan, 2018 - Mar, 2023
-
May, 2016 - Aug, 2016
Awards
2-
Mar, 2011
Papers
21-
Pharmaceuticals, 18(3) 333-333, Feb 26, 2025 Peer-reviewedBackground/Objectives: The risk of fractures associated with immune checkpoint inhibitors (ICIs) is increasing; however, the relationship between fracture risk and potential factors, such as osteoporosis and hyperthyroidism, remains unclear. Methods: Using VigiBase, the World Health Organization's global pharmacovigilance database, we investigated the signals for osteoporosis, hyperthyroidism, and fractures associated with ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, ipilimumab, and tremelimumab) by calculating information components (ICs) and their 95% confidence intervals (CIs). Furthermore, we estimated the association between the occurrence of fractures in patients receiving ICIs and osteoporosis or hyperthyroidism. Results: Signals of hyperthyroidism (IC = 4.66, 95% CI: 4.58–4.73), but not osteoporosis (IC = −1.79, 95% CI: −2.22 to −1.36) or fractures (IC = −0.21, 95% CI: −0.36 to −0.06), were detected in patients using ICIs. Osteoporosis (odds ratio: 118.00, 95% CI: 61.00–230.00) was associated with an increased reporting frequency of fractures related to ICIs, whereas hyperthyroidism (odds ratio: 0.60, 95% CI: 0.19–1.87) was not associated with such an increase. Conclusions: The VigiBase analysis indicates that the use of ICIs does not increase the reporting frequency of osteoporosis or fractures. Additionally, hyperthyroidism did not increase the reporting frequency of fractures associated with ICIs.
-
European Journal of Clinical Pharmacology, 81(3) 441-449, Jan 16, 2025 Peer-reviewedLead authorCorresponding authorAbstract Purpose Tranexamic acid (TXA) is widely used as an antifibrinolytic drug. However, studies to determine the optimal blood concentration of TXA have produced inconsistent results. During cardiac surgery, cardiopulmonary bypass (CPB) has serious effects on drug distribution, elimination, and plasma concentration. Therefore, we aimed to establish a population pharmacokinetics model of TXA in patients undergoing cardiac surgery with CPB that considers renal function as a covariate, thereby facilitating personalized treatment. Methods In total, 453 TXA plasma samples were prospectively collected from 77 patients who underwent cardiac surgery with CPB. Plasma concentrations were determined by ultra-performance liquid chromatography-tandem mass spectrometry. The population pharmacokinetic model of TXA was analyzed using nonlinear mixed-effects modeling. Results The two-compartment–based model with combined errors was determined as the best. The final model included the effect of bodyweight and CLcr may be summarized as V 1 (L) = 12.77 × (bodyweight / 61.4)0.911, V 2 (L) = 6.857, CL1 (L/h) = 3.263 × [CLcr (L/h) / 61.0]0.752, CL2 (L/h) = 2.859. Conclusion Patients who undergo cardiac surgery with CPB may require an adjusted dose of TXA tailored to CPB due to lower CL1 and increased V 1. Our TXA population pharmacokinetic model may be useful for developing individualized dosing designs for TXA in patients who undergo cardiac surgery with CPB.
-
In Vivo, 38(6) 3041-3049, Oct 29, 2024 Peer-reviewed
-
FEBS Open Bio, 14(12) 1955-1971, Oct 10, 2024 Peer-reviewedThe budding yeast Saccharomyces cerevisiae is commonly used as an expression platform for the production of valuable compounds. Yeast‐based genetic research can uniquely utilize auxotrophy in transformant selection: auxotrophic complementation by an auxotrophic marker gene on exogenous DNA (such as plasmids). However, the number of required auxotrophic nutrients restricts the number of plasmids maintained by the cells. We, therefore, developed novel Δ10 strains that are auxotrophic for 10 different nutrients and new plasmids with two multiple cloning sites and auxotrophic markers for use in Δ10 strains. We confirmed that Δ10 strains were able to maintain 10 types of plasmids. Using plasmids encoding model proteins, we detected the co‐expression of 17 different genes in Δ10 cell lines. We also constructed Δ9 strains that exhibited auxotrophy for nine nutrients and increased growth compared to Δ10. This study opens a new avenue for the co‐expression of a large number of genes in eukaryotic cells.
-
In Vivo, 38(3) 1243-1252, Apr 30, 2024 Peer-reviewedLead author
Misc.
39-
Clinical Nutrition ESPEN, 63 1235-1236, Oct, 2024 Peer-reviewed
-
日本泌尿器科学会総会プログラム抄録集 (CD-ROM), 102nd ROMBUNNO.APP-184, 2014
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 121 64P-64P, 2013
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 121 181P-181P, 2013
-
J. Res. Inst. Meijo Univ., 12(12) 35-41, 2013 Peer-reviewed
-
日本薬理学会近畿部会プログラム・要旨集 (Kinki Branch Meeting. Japanese Pharmacological Society), 121st 43, 2012
-
Annual Meeting of the Japanese Society of Toxicology, 35 S190-308, May, 2010
-
Cancer Research, 70(8_Supplement) 3646-3646, Apr 15, 2010 Peer-reviewedLead authorAbstract Platinum(IV) [Pt(IV)] compounds are being developed worldwide as next-generation platinated drugs for a broad range of cancers. Since Pt(IV) compounds show relatively stable structural features, they are applicable for oral administration. The anti-cancer mechanism of Pt(IV) compounds has been proposed as that Pt(II) generated from Pt(IV) by endogenous reductants binds to DNA, resulting in the inhibition of transcription and replication of cancer cells. Here, we investigated the interaction manner between DNA, Pt(IV) and endogenous reductants such as ascorbic acid (AsA) and glutathione (GSH). cis-Diammine-tetrachloro-Pt(IV) [cis-Pt(IV)], which is a prodrug of cisplatin [cis-diammine-dichloro-platinum(II), cis-Pt(II)], was incubated with calf thymus DNA in the presence of AsA or GSH. In the presence of AsA, cis-Pt(IV) induced oxidative damage in calf thymus DNA, in which elevated amount of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), a biomarker for DNA oxidation, was observed. Hydroxyl radical (HO·) scavengers (ethanol and dimethylsulfoxide) suppressed the AsA-associated oxidative damage in a dose-dependent manner, whereas superoxide dismutase and catalase did not, suggesting that HO· was involved in the DNA oxidation. CD spectral change and crosslink formation in calf thymus DNA were also observed during this DNA oxidation, suggesting the cis-Pt(IV) reduction by AsA and the DNA conformational change by cis-Pt(II)-DNA binding. However, GSH did not show any 8-oxodG formation in calf thymus DNA likely due to its own HO· scavenging capability. GSH also suppressed the cis-Pt(II)-like conformational change probably by cis-Pt(II) sequestering from DNA by GSH. This GSH-cis-Pt(II) complex formation was also suggested by agarose gel electrophoresis. In order to reveal the detailed mechanisms of the complex formation, three thiol compounds (2-mercaptoethanol, 2-mercaptoacetic acid, and 2-mercaptoethylamine) were compared with regard to the reductive complex formation capabilities with cis-Pt(II). As observed in GSH-cis-Pt(IV)-DNA system, 2-mercaptoacetic acid and 2-mercaptoethylamine inhibited cis-Pt(II)-induced CD spectral change and crosslink formation in calf thymus DNA, whereas 2-mercaptoethanol did not, suggesting that thiol- and amine-/carbonyl-groups are involved in GSH-cis-Pt(II) complex formation via ligand exchange between these groups and Cl of cis-Pt(II). In this study, we revealed that the interaction manner of cis-Pt(IV) with endogenous reductants. In the reactions, AsA reduced Pt(IV) to Pt(II) and induced DNA-crosslink formation and DNA oxidation, where HO· was produced; GSH scavenged the radical and interfered with the DNA-crosslink formation. These data strongly indicate the importance of the proper Pt(IV) ligands which are suitable for Pt(IV) reduction by endogenous reductants without complex formation with the generated Pt(II). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3646.
-
Annual Meeting of the Japanese Society of Toxicology, 34 S86-3015, Jun, 2009
-
Annual Meeting of the Japanese Society of Toxicology, 33 S128-143, Jun, 2008
-
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128 63-63, 2008
-
J. Res. Inst. Meijo Univ., 7(7) 81-88, 2008 Peer-reviewed
Books and Other Publications
1Presentations
66Professional Memberships
7Research Projects
9-
Apr, 2025 - Mar, 2027
-
研究助成, 公益財団法人 日東学術振興財団, Dec, 2023 - Dec, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
公益財団法人 愛知腎臓財団, Aug, 2023 - Mar, 2024